Optimal drug regimens for primary biliary cirrhosis: a systematic review and network meta-analysis

Author:

Zhu Gui-Qi12,Huang Sha12,Huang Gui-Qian13,Wang Li-Ren12,Lin Yi-Qian13,Wu Yi-Ming12,Shi Ke-Qing14,Wang Jiang-Tao12,Zhou Zhi-Rui5,Braddock Martin6,Chen Yong-Ping14,Zhou Meng-Tao7,Zheng Ming-Hua14

Affiliation:

1. Department of Infection and Liver Diseases, Liver Research Center, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China

2. School of the First Clinical Medical Sciences, Wenzhou Medical University, Wenzhou, China

3. Renji School of Wenzhou Medical University, Wenzhou, China

4. Institute of Hepatology, Wenzhou Medical University, Wenzhou, China

5. Department of Radiation Oncology, Fudan University Shanghai Cancer Center; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China

6. Global Medicines Development, AstraZeneca R&D, Loughborough, United Kingdom

7. Department of Hepatobiliary Surgery, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China

Publisher

Impact Journals, LLC

Subject

Oncology

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3